Cardiovascular efficacy and safety of sodium‐glucose co‐transporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists: a systematic review and network meta‐analysis

Aims To compare the cardiovascular efficacy and safety of sodium‐glucose co‐transporter‐2 ( SGLT 2) inhibitors and glucagon‐like peptide‐1 receptor agonists ( GLP ‐1 RA s) in adults with Type 2 diabetes. Methods Electronic databases were searched from inception to 22 October 2018 for randomized controlled trials designed to assess the cardiovascular efficacy of SGLT 2 inhibitors or GLP ‐1 RA s with regard to a three‐point composite measure of...